The Benefits of Providing External Beam Radiotherapy in Low- and Middle-income Countries.
Identifieur interne : 000290 ( Main/Exploration ); précédent : 000289; suivant : 000291The Benefits of Providing External Beam Radiotherapy in Low- and Middle-income Countries.
Auteurs : M L Yap [Australie] ; T P Hanna [Canada] ; J. Shafiq [Australie] ; J. Ferlay [France] ; F. Bray [France] ; G P Delaney [Australie] ; M. Barton [Australie]Source :
- Clinical oncology (Royal College of Radiologists (Great Britain)) [ 1433-2981 ] ; 2017.
Descripteurs français
- KwdFr :
- MESH :
- radiothérapie : Tumeurs.
- utilisation : Radiothérapie.
- Besoins et demandes de services de santé, Humains, Pays en voie de développement, Prévision, Résultat thérapeutique.
English descriptors
- KwdEn :
- MESH :
- radiotherapy : Neoplasms.
- utilization : Radiotherapy.
- Developing Countries, Forecasting, Health Services Needs and Demand, Humans, Treatment Outcome.
Abstract
More than half of all cancer diagnoses worldwide occur in low- and middle-income countries (LMICs) and the incidence is projected to rise substantially within the next 20 years. Radiotherapy is a vital, cost-effective treatment for cancer; yet there is currently a huge deficit in radiotherapy services within these countries. The aim of this study was to estimate the potential outcome benefits if external beam radiotherapy was provided to all patients requiring such treatment in LMICs, according to the current evidence-based guidelines. Projected estimates of these benefits were calculated to 2035, obtained by applying the previously published Collaboration for Cancer Outcomes, Research and Evaluation (CCORE) demand and outcome benefit estimates to cancer incidence and projection data from the GLOBOCAN 2012 data. The estimated optimal radiotherapy utilisation rate for all LMICs was 50%. There were about 4.0 million cancer patients in LMICs who required radiotherapy in 2012. This number is projected to increase by 78% by 2035, a far steeper increase than the 38% increase expected in high-income countries. National radiotherapy benefits varied widely, and were influenced by case mix. The 5 year population local control and survival benefits for all LMICs, if radiotherapy was delivered according to guidelines, were estimated to be 9.6% and 4.4%, respectively, compared with no radiotherapy use. This equates to about 1.3 million patients who would derive a local control benefit in 2035, whereas over 615 000 patients would derive a survival benefit if the demand for radiotherapy in LMICs was met. The potential outcome benefits were found to be higher in LMICs. These results further highlight the urgent need to reduce the gap between the supply of, and demand for, radiotherapy in LMICs. We must attempt to address this 'silent crisis' as a matter of priority and the approach must consider the complex societal challenges unique to LMICs.
DOI: 10.1016/j.clon.2016.11.003
PubMed: 27916340
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: 001160
- to stream PubMed, to step Curation: 001157
- to stream PubMed, to step Checkpoint: 001157
- to stream Ncbi, to step Merge: 003F84
- to stream Ncbi, to step Curation: 003F84
- to stream Ncbi, to step Checkpoint: 003F84
- to stream Main, to step Merge: 000285
- to stream Main, to step Curation: 000290
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">The Benefits of Providing External Beam Radiotherapy in Low- and Middle-income Countries.</title><author><name sortKey="Yap, M L" sort="Yap, M L" uniqKey="Yap M" first="M L" last="Yap">M L Yap</name><affiliation wicri:level="1"><nlm:affiliation>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales, Australia; Liverpool and Macarthur Cancer Therapy Centres, Western Sydney University, Campbelltown, New South Wales, Australia. Electronic address: mei.yap@sswahs.nsw.gov.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales, Australia; Liverpool and Macarthur Cancer Therapy Centres, Western Sydney University, Campbelltown, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Hanna, T P" sort="Hanna, T P" uniqKey="Hanna T" first="T P" last="Hanna">T P Hanna</name><affiliation wicri:level="1"><nlm:affiliation>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales, Australia; Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales, Australia; Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Shafiq, J" sort="Shafiq, J" uniqKey="Shafiq J" first="J" last="Shafiq">J. Shafiq</name><affiliation wicri:level="1"><nlm:affiliation>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Ferlay, J" sort="Ferlay, J" uniqKey="Ferlay J" first="J" last="Ferlay">J. Ferlay</name><affiliation wicri:level="3"><nlm:affiliation>International Agency for Research on Cancer, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>International Agency for Research on Cancer, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Bray, F" sort="Bray, F" uniqKey="Bray F" first="F" last="Bray">F. Bray</name><affiliation wicri:level="3"><nlm:affiliation>International Agency for Research on Cancer, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>International Agency for Research on Cancer, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Delaney, G P" sort="Delaney, G P" uniqKey="Delaney G" first="G P" last="Delaney">G P Delaney</name><affiliation wicri:level="1"><nlm:affiliation>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales, Australia; Liverpool and Macarthur Cancer Therapy Centres, Western Sydney University, Campbelltown, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales, Australia; Liverpool and Macarthur Cancer Therapy Centres, Western Sydney University, Campbelltown, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Barton, M" sort="Barton, M" uniqKey="Barton M" first="M" last="Barton">M. Barton</name><affiliation wicri:level="1"><nlm:affiliation>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:27916340</idno><idno type="pmid">27916340</idno><idno type="doi">10.1016/j.clon.2016.11.003</idno><idno type="wicri:Area/PubMed/Corpus">001160</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001160</idno><idno type="wicri:Area/PubMed/Curation">001157</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">001157</idno><idno type="wicri:Area/PubMed/Checkpoint">001157</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">001157</idno><idno type="wicri:Area/Ncbi/Merge">003F84</idno><idno type="wicri:Area/Ncbi/Curation">003F84</idno><idno type="wicri:Area/Ncbi/Checkpoint">003F84</idno><idno type="wicri:Area/Main/Merge">000285</idno><idno type="wicri:Area/Main/Curation">000290</idno><idno type="wicri:Area/Main/Exploration">000290</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">The Benefits of Providing External Beam Radiotherapy in Low- and Middle-income Countries.</title><author><name sortKey="Yap, M L" sort="Yap, M L" uniqKey="Yap M" first="M L" last="Yap">M L Yap</name><affiliation wicri:level="1"><nlm:affiliation>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales, Australia; Liverpool and Macarthur Cancer Therapy Centres, Western Sydney University, Campbelltown, New South Wales, Australia. Electronic address: mei.yap@sswahs.nsw.gov.au.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales, Australia; Liverpool and Macarthur Cancer Therapy Centres, Western Sydney University, Campbelltown, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Hanna, T P" sort="Hanna, T P" uniqKey="Hanna T" first="T P" last="Hanna">T P Hanna</name><affiliation wicri:level="1"><nlm:affiliation>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales, Australia; Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario, Canada.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales, Australia; Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Ontario</wicri:regionArea><wicri:noRegion>Ontario</wicri:noRegion></affiliation></author><author><name sortKey="Shafiq, J" sort="Shafiq, J" uniqKey="Shafiq J" first="J" last="Shafiq">J. Shafiq</name><affiliation wicri:level="1"><nlm:affiliation>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Ferlay, J" sort="Ferlay, J" uniqKey="Ferlay J" first="J" last="Ferlay">J. Ferlay</name><affiliation wicri:level="3"><nlm:affiliation>International Agency for Research on Cancer, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>International Agency for Research on Cancer, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Bray, F" sort="Bray, F" uniqKey="Bray F" first="F" last="Bray">F. Bray</name><affiliation wicri:level="3"><nlm:affiliation>International Agency for Research on Cancer, Lyon, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>International Agency for Research on Cancer, Lyon</wicri:regionArea><placeName><region type="region">Auvergne-Rhône-Alpes</region><region type="old region">Rhône-Alpes</region><settlement type="city">Lyon</settlement></placeName></affiliation></author><author><name sortKey="Delaney, G P" sort="Delaney, G P" uniqKey="Delaney G" first="G P" last="Delaney">G P Delaney</name><affiliation wicri:level="1"><nlm:affiliation>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales, Australia; Liverpool and Macarthur Cancer Therapy Centres, Western Sydney University, Campbelltown, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales, Australia; Liverpool and Macarthur Cancer Therapy Centres, Western Sydney University, Campbelltown, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author><author><name sortKey="Barton, M" sort="Barton, M" uniqKey="Barton M" first="M" last="Barton">M. Barton</name><affiliation wicri:level="1"><nlm:affiliation>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Ingham Institute for Applied Medical Research, University of New South Wales, Liverpool, New South Wales</wicri:regionArea><wicri:noRegion>New South Wales</wicri:noRegion></affiliation></author></analytic><series><title level="j">Clinical oncology (Royal College of Radiologists (Great Britain))</title><idno type="eISSN">1433-2981</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Developing Countries</term><term>Forecasting</term><term>Health Services Needs and Demand</term><term>Humans</term><term>Neoplasms (radiotherapy)</term><term>Radiotherapy (utilization)</term><term>Treatment Outcome</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Besoins et demandes de services de santé</term><term>Humains</term><term>Pays en voie de développement</term><term>Prévision</term><term>Radiothérapie (utilisation)</term><term>Résultat thérapeutique</term><term>Tumeurs (radiothérapie)</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Neoplasms</term></keywords><keywords scheme="MESH" qualifier="radiothérapie" xml:lang="fr"><term>Tumeurs</term></keywords><keywords scheme="MESH" qualifier="utilisation" xml:lang="fr"><term>Radiothérapie</term></keywords><keywords scheme="MESH" qualifier="utilization" xml:lang="en"><term>Radiotherapy</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Developing Countries</term><term>Forecasting</term><term>Health Services Needs and Demand</term><term>Humans</term><term>Treatment Outcome</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Besoins et demandes de services de santé</term><term>Humains</term><term>Pays en voie de développement</term><term>Prévision</term><term>Résultat thérapeutique</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">More than half of all cancer diagnoses worldwide occur in low- and middle-income countries (LMICs) and the incidence is projected to rise substantially within the next 20 years. Radiotherapy is a vital, cost-effective treatment for cancer; yet there is currently a huge deficit in radiotherapy services within these countries. The aim of this study was to estimate the potential outcome benefits if external beam radiotherapy was provided to all patients requiring such treatment in LMICs, according to the current evidence-based guidelines. Projected estimates of these benefits were calculated to 2035, obtained by applying the previously published Collaboration for Cancer Outcomes, Research and Evaluation (CCORE) demand and outcome benefit estimates to cancer incidence and projection data from the GLOBOCAN 2012 data. The estimated optimal radiotherapy utilisation rate for all LMICs was 50%. There were about 4.0 million cancer patients in LMICs who required radiotherapy in 2012. This number is projected to increase by 78% by 2035, a far steeper increase than the 38% increase expected in high-income countries. National radiotherapy benefits varied widely, and were influenced by case mix. The 5 year population local control and survival benefits for all LMICs, if radiotherapy was delivered according to guidelines, were estimated to be 9.6% and 4.4%, respectively, compared with no radiotherapy use. This equates to about 1.3 million patients who would derive a local control benefit in 2035, whereas over 615 000 patients would derive a survival benefit if the demand for radiotherapy in LMICs was met. The potential outcome benefits were found to be higher in LMICs. These results further highlight the urgent need to reduce the gap between the supply of, and demand for, radiotherapy in LMICs. We must attempt to address this 'silent crisis' as a matter of priority and the approach must consider the complex societal challenges unique to LMICs.</div></front></TEI><affiliations><list><country><li>Australie</li><li>Canada</li><li>France</li></country><region><li>Auvergne-Rhône-Alpes</li><li>Rhône-Alpes</li></region><settlement><li>Lyon</li></settlement></list><tree><country name="Australie"><noRegion><name sortKey="Yap, M L" sort="Yap, M L" uniqKey="Yap M" first="M L" last="Yap">M L Yap</name></noRegion><name sortKey="Barton, M" sort="Barton, M" uniqKey="Barton M" first="M" last="Barton">M. Barton</name><name sortKey="Delaney, G P" sort="Delaney, G P" uniqKey="Delaney G" first="G P" last="Delaney">G P Delaney</name><name sortKey="Shafiq, J" sort="Shafiq, J" uniqKey="Shafiq J" first="J" last="Shafiq">J. Shafiq</name></country><country name="Canada"><noRegion><name sortKey="Hanna, T P" sort="Hanna, T P" uniqKey="Hanna T" first="T P" last="Hanna">T P Hanna</name></noRegion></country><country name="France"><region name="Auvergne-Rhône-Alpes"><name sortKey="Ferlay, J" sort="Ferlay, J" uniqKey="Ferlay J" first="J" last="Ferlay">J. Ferlay</name></region><name sortKey="Bray, F" sort="Bray, F" uniqKey="Bray F" first="F" last="Bray">F. Bray</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000290 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000290 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:27916340
|texte= The Benefits of Providing External Beam Radiotherapy in Low- and Middle-income Countries.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:27916340" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |